Brookline upgraded Outlook Therapeutics to Buy from Hold with a $1.57 price target. The company announced an equity financing that will fund the NORSE EIGHT trial and commercialization of ONS-5010, the analyst tells investors in a research note. The firm says these actions remove the financing overhang over the shares and reduce regulatory risk for ONS-5010.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OTLK:
